Osteonin Nasal Solution contains Calcitonin (Salmon) 200 IU as its active ingredient, a synthetic peptide hormone used primarily in the management of osteoporosis and other metabolic bone diseases. Calcitonin acts by inhibiting osteoclastic bone resorption, thereby reducing bone loss and increasing bone density. This nasal formulation offers a non-invasive route of administration, enhancing patient compliance compared to injectable forms. Osteonin is indicated for the treatment of postmenopausal osteoporosis in women who are at least five years postmenopause and for Paget’s disease of bone. The nasal spray delivers a precise dose of calcitonin directly to the nasal mucosa, facilitating rapid absorption into systemic circulation. It is contraindicated in patients with hypersensitivity to salmon calcitonin or any component of the formulation. Common adverse effects may include nasal irritation, rhinitis, and occasional epistaxis. Osteonin should be used with caution in patients with a history of hypersensitivity reactions. The recommended dosage is one spray daily, alternating nostrils to minimize local irritation. Regular monitoring of bone mineral density and clinical response is advised during therapy. Osteonin Nasal Solution provides an effective therapeutic option for bone disorders requiring inhibition of excessive bone resorption.